Analogue-based drug discovery III / edited by János Fischer, C. Robin Ganellin, David P. Rotella.

Online resource; title page from PDF title page (viewed June 30, 2014).

General Aspects. Pioneer and Analogue Drugs / Janos Fischer, C Robin Ganellin, David P Rotella -- Competition in the Pharmaceutical Drug Development / Christian Tyrchan, Fabrizio Giordanetto -- Metabolic Stability and Analogue-Based Drug Discovery / Amit S Kalgutkar, Antonia F Stepan -- Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / A Ganesan -- Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / Joseph A Jakubowski, Atsuhiro Sugidachi -- Selective Estrogen Receptor Modulators / Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / Kazumi Kondo, Hidenori Ogawa -- The Development of Cysteinyl Leukotriene Receptor Antagonists / Peter R Bernstein -- Case Studies. The Discovery of Dabigatran Etexilate / Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- The Discovery of Citalopram and Its Refinement to Escitalopram / Klaus P Bogeso, Connie Sanchez -- Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / Helmut Buschmann -- Novel Taxanes: Cabazitaxel Case Study / Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- A New-Generation Uric Acid Production Inhibitor: Febuxostat / Ken Okamoto, Shiro Kondo, Takeshi Nishino.

Includes bibliographical references and index.

"Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and--together with the previous volumes--constitutes the first systematic approach to drug analogue development"--Publisher's website.